Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients

Transplantation Proceedings

Volumn 35, Issue 8, 2003, Pages 2873-2877

  Florea, N R ^a   Capitano, B ^b   Nightingale, C H ^c   Hull, D ^c   Leitz, G J ^d   Nicolau, D P ^c  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

^d Ortho Biotech Products LP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ITRACONAZOLE;

ADULT; ARTICLE; ASPERGILLUS; BLOOD SAMPLING; CALCULATION; CANDIDA; CHEMICAL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HUMAN; INFECTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; STEADY STATE;

EID: 0347131358     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.10.058     Document Type: Article

References (16)

1. Nampoory M.R., Khan Z.U., Johny K.V., et al. Invasive fungal infections in renal transplant recipients. J Infect. 33:1996;95.
2. Abbott K.C., Hypolite I., Poropatich R.K., et al. Hospitalizations for fungal infections after renal transplantation in the United States. Trans Infec Dis. 3:2001;203.
3. Hibberd P.L., Rubin R.H. Renal transplantation and related infections. Semin Respir Infect. 8:1993;216.
4. Como J.A., Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 330:1994;263.
5. Myoken Y., Sugata T., Kyo T., et al. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. J Periodontol. 73:2002;33.
6. Hay R.J., Clayton Y.M. Treatment of chronic dermatophytosis and chronic oral candidosis with itraconazole. Rev Infect Dis. 9:(suppl 1):1987;114.
7. Galimberti R.L., Flores V., Gonzalez Ramos M.C., et al. Cutaneous ulcers due to Candida albicans in an immunocompromised patient - response to therapy with itraconazole. Clin Exp Dermatol. 14:1989;295.
8. Lindholm A., Kahan B.D. Influence of cyclosproien pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmcol Ther. 54:1993;205.
9. Schroeder T.J., Hariharin S., First M.R. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc. 26:1994;2787.
10. Levy G.A. Relationship of pharmacokinetics to clinical outcomes. Transplant Proc. 31:1999;1654.
11. Lindholm A. Cyclosporine A clinical experience and therapeutic drug monitoring . Ther Drug Monit. 17:1995;631.
12. Kramer M.R., Merin G., Rudis E., et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant Proc. 29:1997;2657.
13. McLachlan A.J., Trett S.E. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. Ther Drug Monit. 20:1998;390.
14. Product Information: Sporanox® itraconazole oral solution, Ortho Biotech, Raritan, New Jersey, 2002.
15. Woestenborghs R., Lorreyne W., Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr. 413:1997;332.
16. Campana C., Regazzi M.B., Buggia I., et al. Clinically significant drug interactions with cyclosporine. An update. Clin Pharmacokinet. 32:1997;173.